Law360, New York (December 23, 2010, 8:19 PM ET) -- Sun Pharmaceutical Industries Inc. could be one step closer to selling a generic version of the colon cancer drug Eloxatin after convincing a federal appeals court to vacate and remand a settlement and injunction that a lower court had approved despite Sun's opposition.
A panel of judges in the U.S. Court of Appeals for the Federal Circuit on Wednesday ruled that the lower court was wrong to approve, over objections from Sun, an altered consent judgment filed by Sanofi-Aventis U.S. LLC.
"Sun was... denied the opportunity...
Fed. Circ. Nixes Deal In Sun Pharma Eloxatin Suit
To view the full article, take a free trial now.
